Form 4: Collegium Pharmaceutical EVP and General Counsel Sells Shares After Option Exercise

Shirley R. Kuhlmann, EVP and General Counsel of Collegium Pharmaceutical, exercised stock options and sold shares between March 4th and March 6th, 2025.

Summary

• Shirley R. Kuhlmann, EVP and General Counsel of Collegium Pharmaceutical, executed transactions involving the company's stock.
• On March 4, 2025, Kuhlmann exercised a stock option for 40,000 shares at a price of $24.03 per share.
• Also on March 4, 2025, Kuhlmann sold 40,000 shares at a weighted average price of $28.079 per share, with prices ranging from $28.00 to $28.24.
• On March 5, 2025, Kuhlmann sold 20,000 shares at a weighted average price of $28.0264 per share, with prices ranging from $28.00 to $28.18.
• On March 6, 2025, Kuhlmann sold 26,067 shares at a weighted average price of $28.5014 per share, with prices ranging from $28.50 to $28.58.
• Following these transactions, Kuhlmann directly owns 108,137 shares of Collegium Pharmaceutical.
• The stock option was fully vested and exercisable as of March 4, 2025, and expires on April 4, 2028.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reflects routine insider trading activity (exercise of options and subsequent sale of shares). It doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The stock option was fully vested, indicating a potential reward for past performance.

Risks

• The sale of a significant number of shares by an executive could be interpreted negatively by the market, although it may simply be for personal financial management.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future stock performance.

Comparison to Industry Standards

• Insider selling is a common occurrence in publicly traded companies.
• The impact of insider selling on stock price varies depending on the size of the sale, the individual's position in the company, and overall market conditions.
• It's important to compare Kuhlmann's transactions with those of other executives in similar pharmaceutical companies to assess whether this activity is unusual.

Stakeholder Impact

• The sale of shares by a high-ranking executive could create uncertainty among shareholders, although the impact is likely to be minimal given the relatively small percentage of total shares outstanding.

Key Dates